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A comparative study of short-term efficacy and safety for thyroid micropapillary
carcinoma patients after microwave ablation or surgery
Jianming Lia, Yujiang Liua, Jibin Liub, Peipei Yanga, Xiangdong Hua and Linxue Qiana
aDepartment of Ultrasound, Beijing Friendship Hospital, Capital Medical University, Beijing, China; bDepartment of Radiology, Thomas
Jefferson University, Philadelphia, PA, USA
ABSTRACT
Background: Although papillary thyroid microcarcinoma (PTMC) has a high incidence and excellent
clinical outcome, debate continues as to the therapeutic approach that would be most appropriate
after confirming the diagnosis.
Methods: We retrospectively analyzed the medical records of 311 patients with T1aN0M0 PTMC
between January 2013 and September 2018. In all, 168 underwent microwave ablation (MWA), and
143 underwent surgery. MWA was performed using extensive ablation with hydrodissection. The sur-
gery comprised thyroid lobectomy (TL) with unilateral central lymph node dissection (CND). We exam-
ined clinical outcomes during mean follow-up periods of 824±452days for the TL group and
753±520days for the MWA group.
Results: Postprocedural follow-up revealed that, in the MWA group, the tumors had completely disap-
peared in 34 patients, and the remainder were reduced to necrotic or carbonized tissue. The incidence
of transient hypoparathyroidism was significantly lower in the MWA group than in the TL group
(p< .001). In addition, during the follow-up, we found no statistically significant differences between
the two groups (TL vs MWA) for PTMC recurrence (1 vs 2 cases), lymph node metastasis (5 vs 5 cases),
or disease-free survival [2001days (5.5 years) vs 1702days (4.7 years)] (p¼ .659, p¼ .795, and p¼ .974,
respectively).
Conclusions: If low-risk thyroid carcinoma (i.e., T1N0M0 PTMC) is accurately diagnosed early, MWA
could be a minimally invasive alternative to surgery based on our short-term follow-up regarding
recurrence and the low rates of complications and disease-free survival.
ARTICLE HISTORY
Received 13 February 2019
Revised 15 May 2019







The recorded incidence of papillary thyroid microcarcinoma
(PTMC) has recently increased following widespread screen-
ing and technical improvements in thyroid ultrasonography
(US) and fine-needle aspiration biopsy (FNAC) [1–3]. Despite
this increased incidence, the mortality rate remains
unchanged at 0.5 deaths per 100 000, although the long-
term prognosis is usually excellent, with 10-year survival
rates of up to 98% [4–6]. The American Thyroid Association
(ATA) guidelines [7] recommend active surveillance, but
many patients refuse this approach because of the possibility
of lymph node and distant metastases. Currently, thyroid lob-
ectomy (TL) is commonly used to treat PTMC [8]. A disadvan-
tage of traditional surgery is the high rate of severe
complications, with morbidity exceeding that of the disease
itself [8]. Hence, the ideal PTMC treatment is still controver-
sial [9].
With advances in medical technology, thermal ablation
has emerged as a new strategy. The thyroid radiofrequency
ablation guideline [10] reported that radiofrequency ablation,
microwave ablation (MWA), and laser ablation effectively
ablate local PTMCs over the short term and after a 4-year
follow-up period. MWA provides a high intratumoral tem-
perature, allows ablation of large volumes, and has a rapid
ablation speed. It may also be far less invasive than surgery
[11,12]. Many studies have confirmed that MWA treats soli-
tary T1aN0M0 PTMCs effectively [13,14]. We also confirmed
the effectiveness of MWA in an earlier study of thermal abla-
tion versus surgery for PTMC [15].
The present study aimed to compare follow-up outcomes
for MWA versus surgery, focusing on lymph node metastasis,
recurrence, and postoperative complications.
Materials and methods
Patients
The institutional review board of the Beijing Friendship
Hospital at Capital Medical University approved the study,
and informed consent was obtained from all patients before
surgery or MWA.
CONTACT Linxue Qian, Qianlinxue2002@163.com Department of Ultrasound, Beijing Friendship Hospital, Capital Medical University, No. 95 Yongan Road,
Xicheng District, Beijing 100050, China.
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Altogether, 220 PTMC patients were treated with US-
guided MWA between January 2013 and September 2018.
Among them, 52 patients were excluded (32 were lost to fol-
low-up, and 20 had incomplete information). The remaining
168 patients were enrolled in this study as group A (the
MWA group). We also selected 143 patients without clinical
or US evidence of neck lymph node metastasis (cN0) in
chronological order for the surgical group (group B).
All enrolled patients fulfilled the following criteria: (1) soli-
tary PTMC confirmed by US-guided FNAC; (2) presence of a
solitary tumor measuring 10mm along its greatest dimen-
sion; (3) tumor did not contact or distort the thyroid capsule;
(4) no extra-thyroidal spread (to the trachea or esophagus);
(5) no lymph node involvement identified on imaging or
biopsy evaluation; (6) no history of neck irradiation. The
MWA patients (group A) were ineligible for, or refused to
undergo, surgery because they were either considered at
too-high risk for thyroid surgery or for other reasons. The
group B patients had requested surgery because of physical
or psychological discomfort or neck extension disorders that
made MWA intolerable. The exclusion criteria were (1) biopsy
confirmation of a different carcinoma or a coexisting thyroid
malignancy such as medullary carcinoma; (2) imaging exami-
nations or biopsy that revealed lymph node or distant
metastasis; (3) pregnancy; (4) presence of severe heart,
respiratory, liver, or renal failure; (5) presence of a coagula-
tion disorder associated with a severe bleeding tendency
(Figure 1).
Preoperative assessment for all patients
All included patients underwent a preoperative physical
examination that involved high-resolution neck US examin-
ation of suspicious tumors or lymph nodes to confirm the
number of lesions (single or multiple) (TI-RADS 4a) [16] in
the thyroid gland, followed by FNAC. All patients were for-
bidden to take antiplatelet or anticoagulant medications for
at least 1week before surgery.
Exclusion and diagnostic standards of lymph
node metastasis
US findings of lymph node metastasis were as follows: round
shape (length/short diameter ratio <2:1); unclear division of
cortex and medulla; absent hilus; irregular margins; fusion
tendency; peripheral halo; high-echo, low-echo, or cortical
calcification [17]. Two doctors (LQ, XH) with more than
10 years of experience assessed the lymph node status.
When more than two US images exhibited features of lymph
node metastasis, we defined the lymph node as “suspicious,”
which was then confirmed by FNAC.
MWA instruments and procedures
Before the MWA procedure, each group A patient underwent
US and contrast-enhanced US (CEUS) to determine the site,
vascularity, and size of the tumor [18]. Two doctors (LQ, YL),
each with more than 5 years of experience, performed the
MWA using HI VISION Ascendus (Hitachi, Tokyo, Japan)
equipped with a 5- to 12-MHz linear-array transducer. The
patient was placed supine with the neck fully exposed and
with continuous electrocardiographic, respiratory, and blood
pressure monitoring. Routine sterile skin preparation was
performed with 1% lidocaine as topical anesthesia. A mixture
of 1% lidocaine and physiological saline solution was care-
fully injected into the thyroid capsule as hydrodissection to
protect major structures (carotid vessels, trachea, recurrent
laryngeal nerve, esophagus) from thermal injury [19].
MWA was performed using the moving-shot technique for
multipoint and multidimensional ablation from the tumor’s
Figure 1. Flow chart of the management of papillary thyroid carcinoma (PTMC) using microwave ablation (MWA) or surgery. FNAC, fine-needle aspiration biopsy.
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lower pole to its upper pole [15]. A 17-gauge ablation needle
was inserted into the tumor’s lower pole under US guidance.
The tumor and adjacent thyroid gland were included in the
ablated zone (5mm) to prevent marginal recurrence. A
power output of 30W at 2450MHz for 20–120 s was rou-
tinely used, inducing coagulation necrosis in the tumor. The
therapy was sustained until the entire tumor was hypere-
choic. When withdrawing the antenna, the needle track was
coagulated to prevent tumor cell seeding. We spoke with
the patients intermittently during the entire procedure to
monitor their vocal status. At 1 h after MWA completion,
CEUS was repeated to evaluate the ablated area.
Surgical procedures
Surgery for group B patients, performed under general anes-
thesia, was undertaken by general surgeons with 10 years of
clinical experience. The surgical procedure comprised TL (143
patients) with unilateral CND, according to ATA guide-
lines [16].
Postprocedural follow-up
In the MWA group, the size, volume, vascularity, and charac-
teristics of each tumor were carefully evaluated 1 h after
ablation, at each follow-up point (1, 3, 6, 9, and 12months),
and over the years thereafter. Thus, all patients in all groups
underwent neck US every 3–6months postoperatively.
We defined locoregional recurrence as recurrence in thy-
roid tissue. Lymph node recurrence was defined as either
cytological evidence of disease in the central or lateral neck
compartment or evidence of disease on US. A diagnosis of
recurrent PTMC was based on evidence of disease in the
ablated area of the thyroid bed confirmed by FNAC and/or
US. Distant metastasis was defined as evidence of disease
outside the neck. Complications—transient or persistent
hypoparathyroidism confirmed by serum calcium levels
<8.5mg/dl (2.12mmol/l); symptoms of hypocalcemia; transi-
ent or persistent recurrent laryngeal nerve injury (presenting
as voice change, hoarseness)—were carefully monitored after
the procedures and at each follow-up assessment. If sus-
pected, recurrent laryngeal nerve injury was confirmed by
laryngoscopy.
Disease-free survival
Disease-free survival (DFS) following PTMC was defined as
the duration of time from treatment until the lack of disease
and/or recurrence was confirmed postoperatively [20]. Event
occurrence was defined as postoperative lymph node metas-
tasis and/or tumor recurrence [21].
Statistical analysis
Quantitative data measurements are described as mean-
s ± standard deviation (SD) and range. We compared data for
the two groups using Student’s unpaired t test. Categorical
data comparisons were performed using the v2 test or
Fisher’s exact test. Comparisons of changes in the mean
diameter of each tumor before MWA and at each follow-up
were evaluated using the analysis of variance repeated-meas-
ures test. DFS curves were determined using the
Kaplan–Meier estimation and survival curves using the log-
rank test. All analyses were performed with SPSS statistical
software (version 19; IBM, Armonk, NY, USA). p< .05 was
considered to indicate statistical significance.
Results
Postprocedural follow-up findings
The patients’ characteristics are shown in Table 1. There
were no statistically significant differences in age or sex
between groups A and B (p¼ .185 and p¼ .804, respectively).
Therapeutic effect of MWA
At the time of this writing, 89.3% (150/168) of the MWA
patients had undergone more than 1 year of follow-up.
During that time, the tumors in 34 patients had completely
disappeared. One patient’s tumor disappeared as early as
3months after treatment, with the others having completely
disappeared at 6months (eight patients), 9months (seven
patients), and 1 year (18 patients). The remaining patients’
tumors were obviously unchanged 1 year later. CEUS con-
firmed no enhancement, and FNAC showed necrosis.
Changes in the mean diameters after MWA at 1 h and 1, 3, 6,
9, and 12months after MWA are shown in Table 2.
Complications
Transient hypoparathyroidism was recorded in 10 patients in
the surgical group (7%). In contrast, no patients who under-
went MWA developed permanent or transient hypoparathyr-
oidism. Transient recurrent laryngeal nerve palsy was
reported in 6 (4.2%) patients and permanent laryngeal nerve
damage in 1 (0.7%) in the surgical group. The rates of transi-
ent and permanent recurrent laryngeal nerve injury in the
MWA group were 3.6% and 0.6%, respectively. Hence, the
complication rate was significantly lower after MWA than
Table 1. Patients’ characteristics and follow-up duration, by treatment.
MWA Surgery p value
Number of patients 168 143 –
Mean age (range) 47.36 ± 10.75 (24–75) 49.18 ± 11.41 (26–76) .185
Sex (M:F) 36:132 29:114 .804
Mean follow-up days (range) 753 ± 520 (79–1787) 824 ± 452 (46–2235) .069
M: male; F: female; MWA: microwave ablation.
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after surgery (p< .001). In addition, all patients in the surgical
group required thyroid replacement therapy, whereas none
of the patients in the MWA group did so (Table 3).
Recurrence and DFS
Among the 161 patients with PTMC treated with MWA, there
were five lymph node metastatic recurrences [at
180–1326 days (0.5–3.6 years) of follow-up] and two PTMC
recurrences [at 1078–1328 days (3.0–3.7 years) of follow-up].
Thus, during 1–5 years of follow-up, 95.8% (161/168) of
patients in the MWA group experienced no recurrence. For
the 143 PTMC patients who underwent surgery, there were
five lymph node metastatic recurrences [at 382–1696 days
(1.0–4.6 years) of follow-up] and one PTMC recurrence [at a
follow-up of 1348 days (3.7 years)]. The remaining 95.8%
(137/143) of patients experienced no recurrence following
surgery. Finally, in the MWA group, two patients with PTMC
recurrence and three with lymph node metastatic recurrence
underwent a second MWA, and two with lymph node meta-
static recurrence required surgery. In the surgical group, one
patient with PTMC recurrence and one with lymph node
metastatic recurrence required reoperation, and four patients
with lymph node metastatic recurrence underwent MWA.
The mean DFS was 1702 days (range 79–1787 days;
4.7 years) in the MWA group compared with 2001 days (range
46–2235 days; 5.5 years) in the surgical group. There was no
statistically significant difference in the 5-year DFS
between group A (95.8%) and group B (95.5%) (p¼ .974).
The Kaplan–Meier survival plots are shown in Figure 2 and
Table 4.
Table 2. Changes in mean tumor volume at each follow-up after micro-
wave ablation.
Time Mean ± SD p value
Before treatment 81.60 ± 9.99
1 hour 828.86 ± 63.09 <.001a
1 month 454.19 ± 45.86 <.001a
3 month 221.11 ± 26.27 <.001a
6 month 84.70 ± 12.90 <.001a
9 month 37.47 ± 6.51 <.001a
12 month 21.41 ± 4.02 <.001a
aStatistically significant.
Table 3. Recurrence, lymph node metastasis, and complications following thy-
roid lobectomy versus microwave ablation.
MWA Surgery p value
Complications 7/168 (4.2%) 17/143 (11.9%) <.001
Transient hypoparathyroidism 0 10/143 (7%) <.001
Persistent hypoparathyroidism 0 0 NA
Transient voice change 6/168 (3.6%) 6/143 (4.2%) .776
Persistent voice change 1/168 (0.6%) 1/143 (0.7%) .909
Recurrence (%)
PTMC 2/168 (1.2%) 1/143 (0.7%) .659
LNM (%) 5/168 (3.0%) 5/143 (3.5%) .795
Total (%) 7/168 (4.2%) 6/143 (4.2%) .990
Distance metastasis (%) 0 0 NA
Disease-specific mortality 0 0 NA
PTMC: papillary thyroid microcarcinoma; LNM: lymph node metastasis; NA:
not applicable.
Figure 2. Disease-free survival curves show no statistically significant differences between the microwave ablation (MWA) and surgical groups during follow-up.
Cum, cumulative.
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Discussion
Thyroid carcinoma exhibits an interesting phenomenon in
that, despite an increasing disease incidence, the associated
morbidity and mortality rates remain stable. Thyroid cancer
also generates much controversy regarding over-diagnosis
and over-treatment. The ATA guidelines [16] support active
surveillance of patients with low-risk PTMC, especially those
who are at high surgical risk and/or are projected to have a
short lifespan. Nevertheless, most patients considered to
have maintained a stabilized condition prefer to eliminate
the cancer. Along with active surveillance, surgery is there-
fore the most common, traditional treatment, and MWA is an
emerging, minimally invasive approach.
During the period 2008–2017, laser ablation [22–24],
radiofrequency ablation [18], and MWA [13] were reported as
treatments for low-risk PTMC. MWA is more effective than
other ablation techniques because of its good therapeutic
effect and rapid rate of temperature increase [11, 19, 25]. We
reported a significant reduction in the mean lesion volume
(from 81.60 ± 9.99 to 21.41 ± 4.02mm3) and complete dis-
appearance of the ablation zones (22.7%, 34/150) during fol-
low-up, indicating that MWA is an effective “local” treatment
for PTMC.
In contrast, TL is a relatively “complete” surgical procedure
for PTMC with the advantage of low recurrence, but it also
carries a risk of injury to recurrent laryngeal nerves or para-
thyroid glands. Many patients experience postoperative
hoarseness and hypoparathyroidism, thus requiring lifelong
thyroid hormone replacement therapy. In contrast, MWA
minimizes recurrent laryngeal nerve and parathyroid injury
rates because of real-time US guidance and the use of the
hydrodissection technique [19]. Our experience confirms the
reported high rates (7%) of transient hypoparathyroidism
after surgery (TLþ unilateral CND). With zero incidence of
transient hypoparathyroidism in the MWA group, the differ-
ence between groups was statistically significant (p< .001).
We found no statistically significant difference in recurrent
laryngeal nerve injury between the two groups (p¼ .527),
although the rate was somewhat lower in the MWA group.
Compared with RFA and PLA, MWA has the features of ther-
mal conductivity, a faster rate of temperature increase, and
powerful thermal injury [11,25]. Zhang et al. [18] reported
5.43% (5/92) as the overall RFA complication rate. In an
MWA study, the rates of transient and permanent hoarseness
(3.6% and 0.6%) were higher in the present study than the
hoarseness rate (2.7%) reported by Teng et al. [26] but lower
than the 19% rate found by Yue et al. [13]. Korkusuz et al.
[27] reported median pain scores of 3 and 4 points during
RFA and MWA, respectively, and their rates of mild
hematoma after RFA and MWA treatment were 47.3% (26/
55) and 44.7% (21/47), respectively. The complications in the
present study were similar to those in other studies [27,28].
Recurrence is of greater concern than postoperative com-
plications in patients with thyroid carcinoma. US is the most
frequently recommended imaging modality for both pre-
operative and postoperative evaluations of the thyroid gland
and lymph nodes [29]. All patients in our study underwent
preoperative and postoperative follow-up US evaluations,
with FNAC added to address suspicious lesions (to confirm
recurrent disease).
The present study found that 4.2% (7/168) and 4.2% (6/
143) of patients in the MWA and surgical groups, respect-
ively, developed lymph node metastasis and PTMC recur-
rence, with similar rates of neck recurrence in the two
groups. We speculated that it resulted from an antitumor
immune response activated by thermal ablation [30]. Some
studies have suggested that thermal ablation can induce a
so-called abscopal effect—i.e., spontaneous regression of a
remote, non-targeted tumor [31,32]. In our study, recurrent
tumors found after MWA or surgery were successfully treated
by repeat MWA. Repeated operations are usually challenging
for recurrent carcinoma in the thyroid bed and cervical
lymph nodes because of distortion of normal tissue planes
and fibrosis caused by scar tissue. Thus, the 2017 Thyroid
Ablation Guideline [10] recommends ablation to avoid com-
plications. Some studies [33,34] had reported use of MWA to
treat recurrent thyroid carcinoma or metastatic lymph nodes.
Given the high disease-specific survival and lack of dis-
ease-specific mortality among the treatment groups, the
need to perform more radical neck surgery remains contro-
versial [1,8,35]. In our study, there was no disease-specific
mortality or distant metastasis in either treatment group.
Therefore, when considering the short-term survival status
and lack of complications, simply eliminating the tumor may
be the better approach. Based on our results and previous
reports [11,12,14,15,19], MWA appears to be a good alterna-
tive to surgery in low-risk patients (i.e., those with
T1N0M0 PTMCs).
Our study has several limitations. First, the sensitivity of
US to detect lymph node metastases is relatively low
(23–72%), although its specificity is 69–92% [29,36,37]. The
main reason is that region VI is a blind area for US [38].
Second, five patients in the surgical group had multifocal dis-
ease according to the final pathology, which showed small
(1–2mm) and occult (<2mm) carcinomas that could easily
be missed by US [39]. Thus, the conventional examinations
(US, FNAC) could not evaluate a solitary tumor with great
validity. Finally, the follow-up time is short (1.0–3.5 years),
and the number of cases is small.
In conclusion, MWA is superior to surgery in terms of the
appearance of complications and its minimal invasiveness. As
a technique that could accurately assess lymph node and
lesion status preoperatively, and on the basis of our short-
term follow-up for recurrence and the DFS rates, MWA may
be considered an alternative to surgery for low-risk patients
with a PTMC. Above all, the most appropriate treatment for
PTMC has yet to be determined.




Total˂1 1–2 2–3 3–4 4–5 5þ
MWA 18 59 34 33 24 0 168
Surgery 25 49 27 30 10 2 143
MWA: microwave ablation.
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